Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Luminari

Showing results (101-110 of 210) with videos related to

Pageof 21
Sort By:
Cytotherapy|April 1, 2010
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansionGiulia Grisendi, Cecilia Annerén, Luigi Cafarelli, et al.
Blood|March 22, 2018
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL studyAnne Ségolène Cottereau, Annibale Versari, Stefano Luminari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study databasePhilippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, et al.
Hematological Oncology|May 23, 2022
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic studyRexhep Durmo, Benedetta Donati, Louis Rebaud, et al.
Leukemia & Lymphoma|March 21, 2015
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II studyEmilio Iannitto, Stefano Luminari, Claudio Tripodo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano LinfomiTeodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
Blood|November 3, 2012
Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trialAndrés J M Ferreri, Silvia Govi, Markus Raderer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Reply to H.J.A. Adams et al and E. Laffon et alMichel Meignan, Anne Ségolène Cottereau, Annibale Versari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Paolo G Gobbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma PatientsStefano Luminari, Benedetta Donati, Massimiliano Casali, et al.
Pageof 21

Showing results (101-110 of 210) with videos related to

Sort By:
Pageof 21
Cytotherapy|April 1, 2010
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansionGiulia Grisendi, Cecilia Annerén, Luigi Cafarelli, et al.
Blood|March 22, 2018
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL studyAnne Ségolène Cottereau, Annibale Versari, Stefano Luminari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study databasePhilippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, et al.
Hematological Oncology|May 23, 2022
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic studyRexhep Durmo, Benedetta Donati, Louis Rebaud, et al.
Leukemia & Lymphoma|March 21, 2015
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II studyEmilio Iannitto, Stefano Luminari, Claudio Tripodo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano LinfomiTeodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
Blood|November 3, 2012
Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trialAndrés J M Ferreri, Silvia Govi, Markus Raderer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Reply to H.J.A. Adams et al and E. Laffon et alMichel Meignan, Anne Ségolène Cottereau, Annibale Versari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Paolo G Gobbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma PatientsStefano Luminari, Benedetta Donati, Massimiliano Casali, et al.
Pageof 21